whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients

Experts are debating whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients.

The lay press has picked up on a recent meta-analysis linking tiotropium (Spiriva) and ipratropium (Atrovent, Combivent) to a higher risk of cardiovascular events.

But don't jump to conclusions. There are two sides to the story.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote